Differential Intervention Trial by Standard Therapy Versus Pitavastatin in Patients With Chronic Hemodialysis (DIALYSIS)
This study is currently recruiting participants.
Verified March 2009 by Juntendo University Hospital
Sponsor:
Juntendo University Hospital
Information provided by:
Juntendo University Hospital
ClinicalTrials.gov Identifier:
NCT00846118
First received: February 17, 2009
Last updated: June 22, 2011
Last verified: March 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Detailed Description:
The purpose of this study is to verify whether pitavastatin prevents from cardiovascular events and improves the mortality in chronic hemodialysis patients with hypercholesteremia.
Condition | Intervention |
---|---|
Cardiovascular Disease |
Drug: Pitavastatin |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
Official Title: | Differential Intervention Trial by Standard Therapy Versus Pitavastatin in Patients With Chronic Hemodialysis. |
Resource links provided by NLM:
MedlinePlus related topics:
Dialysis
Drug Information available for:
Pitavastatin
U.S. FDA Resources
Further study details as provided by Juntendo University Hospital:
Secondary Outcome Measures:
- cardiac death, myocardial infarction [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Estimated Enrollment: | 1550 |
Study Start Date: | February 2009 |
Estimated Study Completion Date: | February 2015 |
Estimated Primary Completion Date: | February 2014 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Active Comparator: Pitavastatin
Pitavastatin in addition to optimal standard care
|
Drug: Pitavastatin
1-4mg/day
Other Name: LIVALO
|
No Intervention: optimal standard care |
Detailed Description:
It was already proved by the clinical trials that statins prevent from death and cardiovascular events. However, the efficacy of statins in patients with chronic hemodialysis has not been proved yet.
Eligibility
Ages Eligible for Study: | 20 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- patients under hemodialysis
patients with hypercholesterolemia as defined by any of following parameters:
- LDL-C ≧ 100 mg / dL
- TC ≧ 180 mg / dL
- patients required cholesterol-lowering treatment by investigators.
- patients aged 20-75 years
- patients with written consent by their own volition after being provided sufficient explanation for the participation into this clinical trial
Exclusion Criteria:
- patients taking statins or fibrates
- patients enrolled to the other trials using contraindication drugs of pitavastatin
- patients who had acute myocardial infarction within six months before the day of the agreement acquisition
- patients scheduled PCI and CABG within six months after the day of the agreement acquisition
- Patients who had diagnosis or doubt of malignant tumor
- patients corresponded to "Contraindications" of pitavastatin
- Familial hypercholesterolemia patients
- patients judged ineligible by investigators
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00846118
Contacts
Contact: Yasuhiko Tomino, MD,PhD | +81-35-802-1065 ext N.A. | yasu@juntendo.ac.jp |
Contact: Chieko Hamada, MD,PhD | +81-35-802-1065 ext N.A. | chieko@juntendo.ac.jp |
Locations
Japan | |
Division of Nephrology, Department of Internal Medicine, Juntendo Hospital | Recruiting |
Tokyo, Japan, 113-8421 | |
Contact: Yasuhiko Tomino, MD,PhD +81-35-802-1065 | |
Contact: Chieko Hamada, MD,PhD +81-35-802-1065 | |
Principal Investigator: Yasuhiko Tomino, MD,PhD |
Sponsors and Collaborators
Juntendo University Hospital
Investigators
Principal Investigator: | Yasuhiko Tomino, MD,PhD | Professor of Medicine, Department of Nephrology, Juntendo University Graduate School of Medicine |
More Information
No publications provided
Keywords provided by Juntendo University Hospital:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 26, 2012
No publications provided
Responsible Party: | Yasuhiko Tomino/Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Juntendo University |
ClinicalTrials.gov Identifier: | NCT00846118 History of Changes |
Other Study ID Numbers: | 208-032 |
Study First Received: | February 17, 2009 |
Last Updated: | June 22, 2011 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Keywords provided by Juntendo University Hospital:
Pitavastatin Hemodialysis Mortality Cardiovascular disease |
Additional relevant MeSH terms:
Cardiovascular Diseases Pitavastatin Hydroxymethylglutaryl-CoA Reductase Inhibitors Anticholesteremic Agents Hypolipidemic Agents Antimetabolites |
Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Enzyme Inhibitors Lipid Regulating Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on September 26, 2012